I. Start the exam by click the “Start” button
Chronic hepatitis- Part 3
See all quizzes of Chronic hepatitis at here:
Chronic hepatitis- Part 1| Chronic hepatitis- Part 2| Chronic hepatitis- Part 3| Chronic hepatitis- Part 4
1.PEG stands for ?
A. Polyethylene glycerol
B. Perethylene glycerol
C. Polyethylene glycol
D. Perethylene glycol
2.Pegylated IFN-a was approved by FDA for chronic hepatitis B
in which year ?
A. 2000
B. 2002
C. 2003
D. 2005
3. The recommended regimen of peg IFNa-2a for CHB is ?
A. 180 µg subcutaneously weekly for one month
B. 180 µg subcutaneously weekly for three months
C. 180 µg subcutaneously weekly for six months
D. 180 µg subcutaneously weekly for one year
4. Which of the following HBV genotype has the highest rate of
IFN-induced HBeAg loss ?
A. Genotype A
B. Genotype B
C. Genotype C
D. Genotype D
5. The most potent of the HBV antivirals is ?
A. Entecavir
B. Telbivudine
C. Tenofovir
D. Adefovir Dipivoxil
6. Tenofovir is similar to which of the following ?
A. Entecavir
B. Telbivudine
C. Tenofovir
D. Adefovir Dipivoxil
7.Which of the following is recommended as first-line therapy in
Chronic Hepatitis B ?
A. PEG IFN
B. Entecavir
C. Tenofovir
D. All of the above
8. Therapy with which of the following is least likely to foster
emergence of viral mutations ?
A. Lamivudine
B. Tenofovir
C. Telbivudine
D. Adefovir
9. Which of the following should be avoided or used with extreme
caution during pregnancy ?
A. PEG IFN
B. Adefovir
C. Entecavir
D. All of the above
10.In patients with HBV-HIV infection, which of the should never
be used as monotherapy ?
A. Lamivudine
B. Adefovir
C. Entecavir
D. Tenofovir
11. Variables that favour the treatment of HBV/HIV co-infected
patients with pegylated interferon are all except ?
A. HBeAg-positive
B. Elevated aminotransferases
C. High CD4 counts
D. Psychiatric disorders
12. Which of the following antibody is seen in chronic hepatitis
D ?
A. Anti-LKM1
B. Anti-LKM2
C. Anti-LKM3
D. Anti-LKM4
13. Which of the following antibody is prevalent in patients with
chronic hepatitis C virus (HCV) infection ?
A. Smooth muscle antibodies (SMA)
B. Antinuclear (ANA) antibodies
C. Anti-liver kidney microsomal type 1 (LKM1) antibody
D. All of the above
14. Out of the following, which one is the most important as regards
progression of liver disease in chronic hepatitis C ?
A. Older age
B. Longer duration of infection
C. HIV infection
D. Obesity
15.Best prognostic indicator in chronic hepatitis C is ?
A. Liver histology
B. Severity of jaundice
C. Levels of aminotransferases
D. HIV status
16.Which of the following is the most common symptom in chronic
hepatitis C ?
A. Fatigue
B. Jaundice
C. Fever
D. Weight loss
17. Extrahepatic complications unrelated to immune-complex
injury in chronic hepatitis C are all except ?
A. Sjögren’s syndrome
B. Porphyria cutanea tarda
C. Essential mixed cryoglobulinemia
D. Lichen planus
18.Which of the following in a laboratory feature of chronic
hepatitis C ?
A. Fluctuating aminotransferase levels
B. Jaundice is rare
C. Circulating anti-LKM1 antibodies
D. All of the above
19. Which of the following enhances the efficacy of IFN ?
A. Ribavirin
B. Adefovir
C. Entecavir
D. Tenofovir
20. Rapid virologic response (RVR) is estimated at what time after
institution of therapy in Hepatitis C ?
A. 2 weeks
B. 4 weeks
C. 8 weeks
D. 12 weeks
21. Early virologic response (EVR) is estimated at what time after
institution of therapy in Hepatitis C ?
A. 2 weeks
B. 4 weeks
C. 8 weeks
D. 12 weeks
22. Responder status is estimated at what time after institution of
therapy in Hepatitis C ?
A. 12 weeks
B. 24 weeks
C. 48 weeks
D. 72 weeks
23. Sustained virologic response (SVR) is estimated at what time
after institution of therapy in Hepatitis C ?
A. 12 weeks
B. 24 weeks
C. 48 weeks
D. 72 weeks
